Please login to view this media
- Talk
- 21/09/2022
- UK
Platelet Rich Plasma Injection for Acute Achilles Tendon Rupture: Two-Year Follow-Up of the PATH-2 Randomized, Placebo-Controlled, Superiority Trial
Description
In this presentation, Joseph Alousou discusses the findings of the Path to Trial study, which evaluates the efficacy of Platelet Rich Plasma (PRP) in enhancing the healing process of Achilles tendon ruptures. Covering a two-year follow-up period, Alousou emphasizes the study's rigorous design, being a randomized, placebo-controlled trial involving 230 patients across 19 UK centers. Initial findings published indicated no significant advantages of PRP over placebo at 24 weeks, leading to an extended follow-up to assess long-term recovery outcomes.
The study revealed that, after two years, there were no notable differences in the Achilles tendon rupture scores or quality of life indicators between groups receiving PRP injections and those receiving a placebo. Statistical analyses demonstrated consistent baseline characteristics across groups, further validating the study's robustness. Despite exploring different stratifications and potential correlations in cell concentration and growth factors, the results repeatedly underscored the absence of significant differences.
Alousou concludes by reinforcing that the findings do not advocate for the use of PRP in managing Achilles tendon injuries at this stage, highlighting the necessity for more rigorous trials to establish any measurable benefits of PRP therapy in soft tissue applications. He expresses gratitude to collaborators and funders, closing the session to appreciative applause.